"Pharmaceutical Headline Jun" innovation "snatching" game opened! Several MNCs have entered the game with pitching.

(2020/10/12) Following 6 mergers and acquisitions in the first half of the year, 7 more biopharmaceutical companies were acquired in the third quarter; 34 exclusive Chinese medicine terminals sold more than 320 million varieties bucked the trend; and the suspension of insulin to reverse the rare case of type 1 diabetes NEJM indicates the potential of JAK inhibitors... (Click on the title, can get the original text) "Pharmaceutical 1st time" after the first half of 6 mergers and acquisitions, the third quarter of the U.S. stocks and 7 biopharmaceutical companies were acquired in the first week of October, MYOK, EIDX two listed pharmaceutical companies were acquired, such as Lilly, Sanofi, Anjin and other major pharmaceutical companies have also been acquired rumors.
, six U.S.-listed pharmaceutical companies were acquired in the first half of this year, while in the third quarter, there were seven more mergers and acquisitions.
: One quarter ahead of the first half.
"E drug manager" cast! Innovation "snatching" game opens! A number of MNC has entered the market as a multinational pharmaceutical industry fund for China's innovative healthcare industry, following Lilly Asia Ventures, LAV, and this year AstraZeneta's first global industrial investment fund has been moving.
bi and Sanofi have joined the wave of innovation in China's pharmaceutical industry through indirect methods this year.
Headline Bacteria: The time to β share the dividends of China's pharmaceutical innovation and development is beginning to mature β . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
, however, a young type 1 diabetic may be the lucky one.
the young man had stopped taking insulin and maintained normal blood sugar levels for nearly two years after taking ruxolitinib, a JAK inhibitor.
report on this particular case was recently published in the New England Journal of Medicine, providing important insights into the potential of JAK inhibitors in the field of type 1 diabetes.
: Hopefully JAK inhibitors will also have a really far-reaching effect on type 1 diabetes.
(Mi Net) 34 exclusive Chinese medicine terminal sales of more than 300 million 2 varieties against the trend of the new crown pneumonia outbreak overlay policy support, China's Chinese medicine industry or ushered in a new round of growth, exclusive Chinese medicine benefits will be more obvious.
2019, 34 exclusive Chinese medicines sold more than 300 million yuan in retail pharmacies terminals in Chinese cities, with a total sales of nearly 20 billion yuan, according to the company's data.
: 18 exclusive growth rate of Chinese medicine "run to win" the overall market of Chinese medicine.
.